Vera Therapeutics (NASDAQ:VERA) Given New $125.00 Price Target at HC Wainwright

Vera Therapeutics (NASDAQ:VERA) had its price objective increased by research analysts at HC Wainwright from $110.00 to $125.00 in a research report issued on Wednesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 190.97% from the stock’s previous close.

A number of other research firms have also weighed in on VERA. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Bank of America upped their target price on Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.90.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $42.96 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The firm has a market cap of $3.08 billion, a PE ratio of -7.75 and a beta of 0.92. The business has a 50 day moving average price of $36.29 and a 200-day moving average price of $41.20.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the prior year, the company posted ($0.81) EPS. Equities research analysts predict that Vera Therapeutics will post -6.23 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the sale, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. The trade was a 8.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 59,951 shares of company stock worth $2,392,387 over the last ninety days. Company insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its position in Vera Therapeutics by 49.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after buying an additional 1,795,537 shares in the last quarter. Deerfield Management Company L.P. raised its position in shares of Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after purchasing an additional 293,040 shares during the last quarter. Vanguard Group Inc. boosted its stake in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after purchasing an additional 379,748 shares in the last quarter. Vestal Point Capital LP grew its position in Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Finally, Eversept Partners LP increased its stake in Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock valued at $155,581,000 after purchasing an additional 264,468 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.